-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。オライリー・オートモーティブ(ORLY)の第1四半期EPSは、0.72ドル(前年同期比16%増)となり、市場予想の0.70ドルを上回りました。この好業績は、予想をはるかに上回る既存店売上高(SSS)の伸びが牽引しました。純売上高は10%増の45億6000万ドル(市場予想を1億ドル上回る)となり、SSSの伸びは8.1%(市場予想の5.5%を大きく上回る)でした。また、売上総利益率は20ベーシスポイント上昇し51.5%(市場予想を10ベーシスポイント下回る)となりました。特筆すべきは、ORLYの四半期SSS成長率が2023年第3四半期以来最も高かったことです。ORLYは通期EPSガイダンスを3.10~3.20ドルから3.15~3.25ドルに引き上げました。これは現在のコンセンサスである3.23ドルを上回っています。注目すべきは、同社が第1四半期に8.1%の成長率を記録したにもかかわらず、ガイダンスでは依然として総収益が187億~190億ドル、SSS成長率が3~5%であると想定している点です。ORLY株は現在、時間外取引で6%上昇しています。同社の驚異的なSSS成長が大きな話題となりました。また、同社は通期EPSガイダンスを引き上げましたが、新しいガイダンスの売上高の想定は保守的であるように見え、今年後半にもう一度引き上げられる可能性を示唆しています。
Related Articles
Electro Optic Systems Reports Contract Backlog Growth as of March 31
Electro Optic Systems Holdings (ASX:EOS) reported a contract backlog of AU$518 million as of March 31, up 13% from the end of 2025, according to a Thursday filing with the Australian bourse.The company closed the March quarter with unrestricted cash holdings of AU$95.1 million, representing a decrease of AU$11.8 million from the end of 2025, per the filing.
Regis Healthcare Expects Fiscal 2026 Underlying EBITDA at Top End of Guidance
Regis Healthcare (ASX:REG) said it expects fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) of about AU$135 million, at the top end of guidance, according to a Thursday Australian bourse filing.Occupancy across mature homes averaged about 96% in the fiscal third quarter, per the filing.The company said it generated net refundable accommodation deposit (RAD) cash inflows of AU$44.5 million in the third quarter, taking the total net RAD cash inflows for the year to date to AU$223 million.As resident turnover occurs, the progressive repricing of existing paid-up RADs to current advertised room prices is expected to generate net operating cash inflows of about AU$400 million over time while also increasing RAD retention earnings, the company added.
Research Alert: CFRA Keeps Hold Opinion On Shares Of Mondelez International
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price of $63, raised $1, reflects a 19x multiple of projected 2027 EPS, in line with MDLZ's historical forward P/E average. We raise our 2026 EPS estimate by $0.06 to $3.08, but cut 2027's by $0.11 to $3.32. We continue to see headwinds related to chocolate and biscuits divisions, though favorable forex has been helping to a degree. MDLZ highlighted plans to stimulate growth with more promotional activity, which could boost revenues (we see an acceleration in revenues in 2027), but may come with the trade-off of narrower margins. We note that cost-saving efforts can also contribute to staving off some of the margin pressure. MDLZ is largely hedged on its cocoa input costs for 2026 but less so in 2027. Thus, if the substantial rise in cocoa pricing in 2025 does not reemerge, it should help the bottom line in 2027 as cost pressures should ease. Share buybacks have also contributed to EPS, and we note that Q1 2026 share count was down 1.5% from one year earlier.